Archives

Small improvement seen in global cognition scores, but no different from those following control diet with mild caloric restriction

Mean change in Preclinical Alzheimer Cognitive Composite score not significantly different at 240 weeks with solanezumab, placebo

Counties with the highest prevalence were Miami-Dade County in Florida, Baltimore County in Maryland, and Bronx County in New York

Slows clinical progression at 76 weeks for those with low/medium tau and the combined low/medium and high tau pathology population

Survival estimates that exclude the effects of coexisting conditions lead to underestimation, overestimation of survival

Worse overall survival seen for prolonged median time from surgery to initiation of postoperative radiation

More than half of patients in remission six years after surgery, regardless of weight loss

Risk reduced by more than one-third versus matched individuals without surgery

Women with atrial fibrillation and normal baseline cognition had higher risk of disease progression from normal to MCI, MCI to dementia

Normalization of alanine aminotransferase also seen with bulevirtide 2- or 10-mg